These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 2806070)

  • 1. [The role of the system of reverse capture of dopamine in the development of experimental Parkinsonism under the effect of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and its pyridine analogs].
    Bachurin SO; Soliakov LS; Lermontova NN; Tkachenko SE; Kalashnikov VV; Serkova TP; Petrova LN
    Dokl Akad Nauk SSSR; 1989; 307(3):740-3. PubMed ID: 2806070
    [No Abstract]   [Full Text] [Related]  

  • 2. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
    Kucherianu VG; Kryzhanovskiĭ GN; Kudrin VS; Iurasov VV; Nikushkin EV; Zhigal'tsev IV
    Biull Eksp Biol Med; 1999 May; 127(5):502-5. PubMed ID: 10399565
    [No Abstract]   [Full Text] [Related]  

  • 4. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
    Mizukawa K; Ogawa N; Sora YH
    Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice.
    Gerlach M; Russ H; Winker J; Witzmann K; Traber J; Stasch JP; Riederer P; Przuntek H
    Arzneimittelforschung; 1993 Apr; 43(4):413-5. PubMed ID: 7684224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the capability of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pyridine derivatives to evoke parkinsonism].
    Lermontiva NN; Soliakov LS; Bachurin SO; Tkachenko SE; Serkova TP
    Biull Eksp Biol Med; 1989 Jun; 107(6):699-701. PubMed ID: 2790166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN; Thakar JH; Grimes JD
    Adv Neurol; 1990; 53():219-23. PubMed ID: 2239461
    [No Abstract]   [Full Text] [Related]  

  • 8. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
    Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
    Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV; Kucherianu VG; Kudrin VS; Zhigal'tsev IV; Nikushkin EV; Sandalov IuG; Kaplun AP; Shvets VI
    Biull Eksp Biol Med; 1997 Feb; 123(2):150-3. PubMed ID: 9280483
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
    Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
    Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
    Lermontova NN; Soliakov LS; Bachurin SO; Serkova TP; Petrova LN; Dranyĭ OA; Tkachenko SE; Kalashnikov VV
    Biull Eksp Biol Med; 1990 Oct; 110(10):397-9. PubMed ID: 2279092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
    Hirata Y; Nagatsu T
    Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
    [No Abstract]   [Full Text] [Related]  

  • 14. [Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
    Atadzhanov MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(4):117-21. PubMed ID: 1650080
    [No Abstract]   [Full Text] [Related]  

  • 15. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M; Rojas P; Kravzov J; Rios C
    Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism.
    Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
    J Neural Transm Suppl; 1986; 20():41-6. PubMed ID: 3462325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK; Keyghobadi M; Moore C; Meshul CK
    Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
    Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
    Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.